{"analyses":[{"ciLowerLimit":"-0.75","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.15","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.07","estimateComment":"Week 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.20"},{"ciLowerLimit":"-0.28","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.49","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.78","estimateComment":"Week 2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.10"},{"ciLowerLimit":"-0.93","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.99","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.11","estimateComment":"Week 3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.03"},{"ciLowerLimit":"-2.02","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.02","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.14","estimateComment":"Week 5","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.00"},{"ciLowerLimit":"-3.11","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.51","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.29","estimateComment":"Week 6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-0.80"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.66","upperLimit":"2.64","value":"0.99"},{"groupId":"OG001","lowerLimit":"1.17","upperLimit":"3.20","value":"2.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.03","upperLimit":"2.25","value":"1.11"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.98","value":"2.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.35","upperLimit":"2.89","value":"1.27"},{"groupId":"OG001","lowerLimit":"1.20","upperLimit":"3.41","value":"2.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.27","upperLimit":"3.63","value":"1.95"},{"groupId":"OG001","lowerLimit":"0.82","upperLimit":"3.08","value":"1.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.49","upperLimit":"4.33","value":"2.41"},{"groupId":"OG001","lowerLimit":"0.32","upperLimit":"2.90","value":"1.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-\"no appetite\" to 10-\"very good appetite\", where higher score indicated better appetite.\n\nIn this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score were summarized descriptively by treatment group and timepoint.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received placebo during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG000","title":"Placebo"},{"description":"Participants received PF-06946860 200 mg during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG001","title":"PF-06946860 200mg Q3W"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. The number analyzed at each timepoint in each group was the number of participants with non-missing data in the analysis set at a given visit. Number of participants analyzed = number of participants evaluable for this OM, number analyzed = number of participants evaluable at each timepoint for each treatment group.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 1, 2, 3, 5 and 6","title":"Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}